Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Patrick Schnable, Alex Vodenlich


Patrick Schnable has been named director of Iowa State University's Plant Sciences Institute.

Schnable is currently a professor in ISU's College of Agriculture and Life Sciences, and received the inaugural chair in genetics in ISU's department of agronomy in 2013.

He also founded and directs the Center for Plant Genomics, a center within the Plant Sciences Institute (PSI) and served as the PSI's associate director 2005 to 2010.

Separately, Schnable is managing partner of Data2Bio, a next-generation sequencing services firm.

KromaTiD has hired Alex Vodenlich as its new CEO.

Vodelinch most recently was president and CEO of Gentel Biosciences, a provider of multiplex immunoassay technologies. Prior to GenTel, Vodenlich served as vice president of sales and marketing for PanVera. Before that, he was a discovery research scientist within Pfizer and Abbott Laboratories.

As incoming CEO, Vodenlich said that the company's goals are to build "revenue traction and to initiate collaborations" to support the launch of KromaTiD's dGH chromosome imaging assays.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.